ClinicalTrials.gg
Enrolling by invitationNCT07939425ThyObiomeUpdated Nov 16, 2026

Effects of Wild Thyme Extract on Overweight and Obesity

An interventional study of Wild Thyme extract and Placebo in Overweight and Obesity, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 388 studies in Obesity with a site in Spain — 93 open to participants now, 132 under way, 43 of them phase 3. Obesity · Spain.

Planned enrollment
251st of 330
53 · median 122
Started
2026
with 40 others
No phase
220 of 388
41 open now
Primary completion
2027-09
later than 73 of 131 live
Registered
381st of 388
by date

Among the 388 studies in Obesity with a site in Spain, this one is the 251st largest by planned enrollment of the 330 interventional ones that give a count, is one of 41 that started in 2026, is one of 220 with no phase, reaches primary completion later than 73 of the 131 other live ones, and was the 381st registered.

Obesity

11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

93 of the 388 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 388 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

Overweight and obesity are characterized by excessive or abnormal adiposity and are associated with an increased risk of metabolic dysfunction, chronic low-grade inflammation, and several chronic diseases. While overweight is not classified as a disease in itself, it represents an early stage in the continuum of excess adiposity and is associated with an increased risk of progression to obesity and the development of obesity-related metabolic complications. Therefore, early intervention during the overweight stage may represent a critical opportunity to prevent or delay disease progression to obesity. Increasing evidence indicates that the gut microbiome plays an important role in metabolic homeostasis and may contribute to the development and progression of overweight and obesity through interactions with host metabolism, intestinal barrier function, immune responses, and microbial-derived metabolites.

This randomized, double-blind, placebo-controlled clinical trial will evaluate whether daily supplementation with a chemically characterized wild thyme (Thymus serpyllum L.) extract for 12 weeks can improve body weight and obesity- and overweight-related anthropometric, metabolic, and inflammatory parameters and modulate the gut microbiome in adults with overweight or obesity. Participants will be randomly assigned in a 1:1 ratio to receive either wild thyme extract or a matching placebo. The primary objective is to evaluate the effect of the intervention on change in body weight after 12 weeks of treatment. Secondary objectives include evaluating changes in body composition, waist circumference, metabolic parameters, inflammatory biomarkers, and intestinal microbiome composition. The study will also investigate whether baseline gut microbiome characteristics or changes in the gut microbiome are associated with the clinical response to treatment, with the aim of identifying potential microbiome-based biomarkers of response. By targeting individuals across the spectrum from overweight to obesity, this study aims to explore whether early intervention in excess adiposity may provide an opportunity to improve metabolic health and potentially reduce progression toward more severe obesity and associated complications.

Read the detailed description

Overweight and obesity are characterized by excessive or abnormal adiposity and are associated with alterations in metabolic homeostasis, chronic low-grade inflammation, and an increased risk of developing several chronic diseases. Obesity results from complex interactions among genetic, metabolic, behavioral, environmental, and socioeconomic factors. It is associated with an increased risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, and other obesity-related complications. Although overweight is not considered a disease in itself, it represents an early stage in the continuum of excess adiposity and is associated with an increased risk of progression to obesity and the development of metabolic complications. This stage may therefore represent an important window of opportunity for early intervention. Addressing excess adiposity before the development of established obesity may help prevent or delay its progression and reduce the subsequent burden of obesity-related metabolic alterations. Consequently, interventions that can be implemented at both the overweight and obesity stages may have potential clinical relevance for improving metabolic health and limiting progression toward more severe adiposity. Current approaches to the management of excess adiposity include lifestyle modification, dietary intervention, physical activity, pharmacological treatment, and, in selected individuals with obesity, bariatric procedures. However, achieving and maintaining clinically meaningful improvements in body weight and metabolic health remains challenging. Therefore, complementary strategies capable of simultaneously influencing body weight, metabolic health, inflammation, and intestinal homeostasis can be crucial, particularly when they are implemented at an early stage of excess adiposity. The gut microbiome has emerged as an important regulator of host metabolism and energy homeostasis. Alterations in intestinal microbial composition and function have been associated with overweight and obesity and may influence energy metabolism, intestinal permeability, bile acid metabolism, short-chain fatty acid production, immune regulation, and systemic inflammatory responses. These alterations may occur along the continuum of increasing adiposity and could contribute to the transition from metabolic health toward obesity-associated metabolic dysfunction. Consequently, modulation of the intestinal microbiome represents a potential complementary strategy for improving metabolic health in individuals with overweight or obesity. Wild thyme (Thymus serpyllum L.) is a plant used in Traditional Medicine that contains bioactive compounds, including phenolic compounds and other phytochemicals with antioxidant and anti-inflammatory properties. Previous experimental studies have demonstrated beneficial effects of Thymus serpyllum extract in models of diet-induced obesity, including attenuation of the inflammatory state and modulation of obesity-associated gut dysbiosis. These findings support the potential role of this botanical extract as a complementary intervention for improving metabolic and intestinal homeostasis in individuals with excess adiposity. The present study will extend this research by specifically investigating adults with overweight or obesity and evaluating the potential effects of the intervention on body weight, anthropometric parameters, metabolic health, inflammation, and the intestinal microbiome. Participants will be randomized in a 1:1 ratio to receive either a chemically characterized Thymus serpyllum extract or a matching placebo for 12 weeks. The intervention will be administered orally once daily in capsule form. Anthropometric, body composition, metabolic, and inflammatory parameters will be assessed at baseline and following the 12-week intervention. Fecal samples will be collected at predefined time points for characterization of the intestinal microbiome using metagenomic sequencing. The primary hypothesis is that daily supplementation with Thymus serpyllum extract for 12 weeks will result in a greater reduction in body weight compared with placebo in adults with overweight or obesity. Secondary hypotheses are that the intervention may improve body composition, waist circumference, metabolic parameters, and obesity- and overweight-associated inflammatory alterations and may favorably modulate the composition and functional characteristics of the intestinal microbiome. An additional objective is to investigate whether baseline microbiome characteristics and changes in microbiome composition are associated with the magnitude of clinical response, potentially identifying microbiome-based biomarkers capable of predicting response to the intervention. By including individuals with both overweight and obesity, the study will evaluate the potential effects of the intervention across different stages of excess adiposity. Particular interest will be placed on determining whether intervention at the overweight stage, before the establishment of obesity, may represent a relevant opportunity to improve metabolic health and potentially reduce progression toward obesity and associated complications.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

Keywords

  • overweight
  • obesity
  • gut microbiome
  • Thymus sepyllum
  • Wild Thyme
  • body weight
  • Metabolic health
  • Dysbiosis
  • Dietary supplement
  • Inflammation
04

In context

Obesity Reclassified

11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's planned enrollment of 53 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: 1. Adults aged 18 to 75 years at the time of screening.

2. (BMI) ≥25.0 kg/m² at screening.

3. Participants with overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥30.0 kg/m²).

4. Stable body weight during the predefined period before screening.

5. Willingness to maintain usual dietary and physical activity habits throughout the intervention period.

6. Ability and willingness to provide fecal samples at the predefined study time points.

7. Ability to comply with study procedures and intervention requirements.

8. Ability to understand the study procedures and provide written .

Exclusion Criteria: 1. Systemic antibiotic treatment within the predefined period before enrollment.

2. Presence of established or clinically unstable cardiovascular disease. 3. Pregnancy or breastfeeding. 4. Clinical diagnosis of inflammatory bowel disease. 5. Clinical diagnosis of celiac disease. 6. Major gastrointestinal disease that may interfere with study outcomes. 7. Previous bariatric surgery.

8. Current participation in another interventional clinical trial.

9. Use of drugs within the predefined .

10. Known allergy or to Thymus species or any component of the study product or placebo.

11. Use of probiotics, prebiotics, synbiotics, or other microbiome-modulating supplements during the predefined washout period.

12. Any medical condition that, in the investigator's opinion, may interfere with participant safety, study compliance, interpretation of results, or completion of study procedures.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    Wild Thyme Extract

    Participants assigned to the experimental arm will receive a chemically characterized wild thyme (Thymus serpyllum L.) extract at a total daily dose of 600 mg, administered orally in capsule form once daily for 12 weeks.

    Dietary Supplement: Wild Thyme extract

  • Placebo comparator
    Placebo

    Participants assigned to the placebo arm will receive matching placebo capsules containing microcrystalline cellulose at an equivalent daily administration schedule for 12 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementWild Thyme extract

    Chemically characterized Thymus serpyllum L. extract administered orally at a total daily dose of 600 mg in capsule form once daily for 12 weeks.

  • Dietary supplementPlacebo

    Microcrystalline cellulose, 600 mg/day, administered orally in matching capsules once daily for 12 weeks.

07

What researchers measure

Primary outcomes

  1. Change in body mass index (BMI) from baseline to week 12.

    Change in body mass index (BMI) following a 12-week intervention with a chemically characterized Thymus serpyllum L. extract in adults with overweight or obesity. BMI will be calculated as body weight in kilograms divided by height in meters squared.

    Time frame: Baseline to week 12

08

Study locations

1 site
  • Ibs.Granada
    Granada, Granada 18016, Spain
09

References and documents

Publications

  • 10.3390/antiox11061073

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 3,685 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Nov 16, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Sep 17, 2027
CompletionEst.
Sep 17, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07939425
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Responsible party
Alba Rodriguez Nogales (Senior Lecturer, Universidad de Granada) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 17, 2026
Primary completion
Sep 17, 2027 (estimated)
Completion
Sep 17, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion